Selisistat R-enantiomer is primarily investigated for its potential in treating Huntington's disease, a neurodegenerative disorder. It functions as a selective SirT1 inhibitor, aiming to modulate the disease's progression by targeting specific pathways involved in neurodegeneration. Research focuses on its ability to reduce the accumulation of toxic protein aggregates, a hallmark of Huntington's disease, thereby potentially slowing neuronal damage and improving clinical outcomes. Its application is currently in the experimental and clinical trial stages, with studies exploring its efficacy, safety, and long-term impact on patients.